Archive for the 'Novel Treatments & Drugs' Category

Novel Treatments & Drugs news feed.

Dendritic Cell Therapy Could be used to Treat Mesothelioma

Immunotherapy is a blossoming field that is becoming more advanced. Instead of other treatments that kill healthy cells in addition to killing cancerous cells, immunotherapy uses the body’s immune system to fight cancer cells, leaving healthy non-cancerous cells intact. It is a better treatment because it is very effective, more efficient, and is easier on

more

Phase I Clinical Trial Yields Positive Results In Latest Immunotherapy Treatment

The immune system is the body’s first line of defense when fighting off any illness, attacking foreign organisms or other substances that may harm or threaten the over health of the body. When the immune system is compromised, the body is unable to fight infections and becomes weak as the illness takes over. For those

more

Peripheral Neuropathy Pain Reduced in Mesothelioma Patients

Avastin (bevacizumab) is a type of chemotherapy treatment that slows tumor growth by blocking the protein that is responsible for forming new blood vessels, which is what tumors need to thrive. By blocking these blood vessels, tumor growth is slowed. For those suffering from mesothelioma, hindering tumor growth can greatly improve the quality of life

more

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma. Immunotherapy is a type of

more

Potential New Treatment Acts as a Sealant for Pleural Mesothelioma Tumors

Pleural mesothelioma, caused by exposure to asbestos is a rare cancer – only 3,000 cases are diagnosed in the U.S. each year – but it is highly aggressive. There is no cure for plural mesothelioma but findings published in the Journal of Thoracic and Cardiovascular Surgery reveal that a new type of combination treatment specifically

more

First FDA Approved Treatment for Mesothelioma in 15 Years

In the Fall of 2018 scientists and researchers from Novocure, an oncology company that specializes in treating solid tumors, were hopeful their latest success with Tumor Treating Fields therapy would lead to FDA approval and ultimately, more options for those suffering from mesothelioma. After a successful clinical trial, these hopes became a reality as the

more

Currently Recruiting: Mesothelioma Clinical Trials

When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee.  Many who are suffering from mesothelioma, who have found little or no comfort in traditional treatments, may turn to clinical trials for hope.  Through clinical trials, patients have access

more

Survival Factors for Mesothelioma Highlighted by University of Pittsburgh Medical Center

According to GLOBOCAN 2018 statistics, each year there are 30,443 mesothelioma cases worldwide, and of those 30,443, 25,576 pass away.  With close to 85 percent of those diagnosed succumbing to the disease, mesothelioma remains one of the most deadly cancers as there is no cure. However, surviving a mesothelioma diagnosis is not entirely impossible as

more

Phase III Clinical Trial for Mesothelioma Available in 50 Locations Across the Globe

A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over 20 years in the making.

more

Targeted Immunotherapy Warrants More Research for Those Suffering from Pleural Mesothelioma

Late last month, the Clinical Respiratory Journal released their findings on the efficacy of intrapleural immunotherapy, which is a highly targeted approach of receiving immunotherapy treatment for those suffering from mesothelioma. Mesothelioma is a cancer caused only by asbestos exposure. Since asbestos is the only known cause, mesothelioma is sometimes referred to as “asbestos cancer.”

more

New Clinical Trial Underway for Immunotherapy Treatment; CA-170

A new immunotherapy treatment that has recently been administered to a patient suffering from mesothelioma has researchers and scientists optimistic that if results are positive, this treatment could be more effective than Keytruda, the immunotherapy treatment that has had major success in non-small cell lung cancer  The name of the treatment is CA-170, and while

more

FDA Approves Genetic-Based Cancer Treatment that Could Help Mesothelioma Patients

Correcting genes that allow cancerous tumors to grow is the basis behind gene therapy, a relatively new treatment that is largely in experimental stages. The initial goals of gene therapy were to address hereditary genetic disorders, but other factors such as the sun, smoking, chemical exposure, etc., can all damage and change our DNA and

more

UK Pharmaceutical Company’s Potential Cancer Vaccine Assists in Treating Mesothelioma

Combination treatment therapies are common for those suffering from mesothelioma because the aggressive nature of this asbestos-caused disease makes it difficult to treat effectively.  Ongoing developments and advancements in medicine have also helped mesothelioma patients extend their life and manage pain throughout the years. While there is no cure for mesothelioma, a recent study published

more

Acupuncture as Potential Palliative Care for Mesothelioma Patients

When one thinks of acupuncture, one may envision a nice relaxing trip to a day spa, where after a long massage or a relaxing facial, tension in body can be further relieved through this ancient practice where thin needles are inserted into the body. However, this traditional Chinese medicine may benefit cancer patients by helping

more

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year – showed promise for the triple

more

Last update: April 01, 2019. 03:30:08 pm.